PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Patent application							
of	I	nventor(s)					
for		C:					
	Title	e of invention					
		OR					
In re application of:	NATESAN SELVAKUI	MAR, et al					
Application No.: 10	/613,414	Group No.: N/A					
Filed: JULY 3, 20	03	Examiner: N/A					
or: NOVEL HETEROCYCLIC COMPOUNDS HAVING ANTIBACTERIAL ACTIVITY: PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM							
Commissioner for P. O. Box 1450 Alexandria, VA 22							
BEFO	×	T OFFICE ACTION (37 C.F.R. 1.97(b)) DER 37 C.F.R. 1.8(a) and 1.10*					
		Express Mail label number is mandatory; certification is optional.)					
I hereby certify that, on the	ne date shown below, this correspo	ndence is being:					
	I	MAILING					
deposited with the Valexandria, VA 223		envelope addressed to the Commissioner for Patents, P. O. Box 1					
37	C.F.R. 1.8(a)	37 C.F.R. 1.10*					
with sufficient posts		as "Express Mail Post Office to Addressee" Mailing Label No (mandator					
☐ transmitted by facsi	TRA mile to the Patent and Trademark (ANSMISSION Office. to (703) 872-9306					
Sept. 1 Date: <u>August 30, 2</u>	0004	Signature Janet I. Cord (type or print name of person certifying)					

* Only the date of filing (§ 1.6) will be the date used in a patent term adjustment calculation, although the date on any certificate of mailing or transmission under § 1.8 continues to be taken into account in determining timeliness. See § 1.703(f). Consider "Express Mail Post Office to Addressee" (§ 1.10) or facsimile transmission (§ 1.6(d) for the reply to be accorded the earliest possible filing date for patent term adjustment calculations.

NOTE: 37 C.F.R. 1.98(b): Each U.S. patent listed in an information disclosure statement must be identified by (1) inventor, patent number, and issue date. Each U.S. patent application published listed in an information disclosure statement (2) shall be identified by applicant, patent application publication number, and publication (3) Each U.S. application listed in an information disclosure statement must be identified by the inventor, application number, and filing date. Each foreign patent or published foreign patent application listed in an information (4) disclosure statement must be identified by the country or patent office which issued the patent or published the application, an appropriate document number, and the publication date indicated on the patent or published application. (5) Each publication listed in an information disclosure statement must be identified by publisher, author (fi any), title, relevant pages of the publication,,date, and place of publication.

WARNING: No extension of time can be had under 37 C.F.R. § 1.36 (a) or (b) for filing an IDS. 37 C.F.R. § 1.97(f).

NOTE: The "filing date of a national application" under 37 C.F.R. 1.97(b) has two possible meanings. Where the filing is a direct one to the United States Patent & Trademark office, the filing is defined in 37 C.F.R. 1.53(b) as "the date on which: (1) A specification containing a description pursuant to § 1.71 and at least one claim pursuant to § 1.75; and (2) any drawing required by § 1.81(a), are filed in the Patent and Trademark Office in the name of the actual inventor or inventors as required by § 1.41." 37 C.F.R. 1.97(b)(1). On the other hand, an international application that enters the national stage occurs when the applicant has filed the documents and fees required by 35 U.S.C. § 371(c) within the periods set forth in § 1.494 or § 1.495. 35 U.S.C. § 371(c) requires the filing of the following: (1) the national fee; (2) a copy of the international application, unless already sent by the International Bureau, and an English translation iffiled in another language; (3) amendments under PCT Article 19, with a translation into English if made in another language; (4) an oath or declaration; and (5) a translation into English of any annexes to the international preliminary examination report, if such annexes were made in another language. 37 C.F.R. 1.97(b)(2).

IDENTIFICATION OF TIME OF FILING THE ACCOMPANYING INFORMATION DISCLOSURE STATEMENT

The information disclosure statement submitted herewith is being filed within three months of the filing date of the application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever event occurs last. 37 C.F.R. 1.97(b).

- NOTE: "No certification or fee is due when the filing is made within the above time period. It is advisable to ensure that no Office action has been mailed if the disclosure statement is delayed until after three months from filing."
- NOTE: "An information disclosure statement will be considered to have been filed on the day it was received in the Office, or on an earlier date of a mailing if accompanied by a properly executed certificate of mailing under 37 C.F.R. 1.8, or Express Mail certificate under 37 C.F.R. 1.10. An office action is mailed on the date indicated in the Office action." Notice of April 20, 1992 (1138 O.G. 37-41, 39).
- NOTE: "The term 'national application' includes continuing applications (continuations, divisions, continuationsin-part) so three-months will be measured from the actual filing date of an application as opposed [sic] to the effective date of a continuing application." Notice of April 20, 1992 (1138 O.G. 37-41, 39).

NOTE: "An action on the merits means an action which treats the patentability of the claims in an application, as opposed to only formal or procedural requirements. An action on the merits would, for example, contain a rejection or indication of allowability of a claim or claims rather than just a restriction requirements (37 C.F.R. 1.142) or just a requirement for additional fees to have a claim considered (37 C.F.R. 1.16(d)). Thus, if an application was filed on Jan. 1 and the first Office action on the merits was not mailed until six months later on July 1, the examiner would be required to consider any proper information disclosure statement filed prior to July 1." Notice of April 20, 1992 (1138 O.G. 37-41, 39).

WARNING: "A petition for suspension of action to allow applicant time to submit an information disclosure statement will be denied as failing to present good and sufficient reasons, since 37 C.F.R. 1.97 provides adequate recourse for the timely submission of prior art for consideration by the examiner." Notice of July 6, 1992 (1141 O.G. 63).

If a fee is required, please charge deposit account 12-0425.

Reg. No. 33,778

Tel. No.: (212)708-1887

Customer No.: 00140

SIGNATURE OF PRACTITIONER

JANET I. CORD

(type or print name of practitioner)

P.O. Address

c/o Ladas & Parry LLP 26 West 61st Street New York, N.Y. 10023



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: NATESAN SELVAKUMAR, et al

Application No.: 10/613,414 Group No.: N/A Filed: JULY 3, 2003 Examiner: N/A

For: NOVEL HETEROCYCLIC COMPOUNDS HAVING ANTIBACTERIAL

ACTIVITY: PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL

COMPOSITIONS CONTAINING THEM

Attorney Docket No.: U 014698-7

Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450 Sir:

INFORMATION DISCLOSURE STATEMENT

We draw the attention of the Examiner to the attached references which are also listed on the attached Form PTO-1449.

Respectfully submitted,

JANET I CORD LADAS & PARRY LLP 26 WEST 61ST STREET NEW YORK, NEW YORK 10023

REG.NO.33,778(212)708-1935

CERTIFICATION UNDER 37 C.F.R. SECTIONS 1.8(a) AND 1.10

(When using Express Mail, the Express Mail label number is mandatory;

Express Mail certification is optional.)

I hereby certify that, on the date shown below, this correspondence is being:

MAILING

deposited with the United States Postal Service in an envelope addressed to the Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450.

37 C.F.R. Section 1.8(a)

37 C.F.R. Section 1.10

TRANSMISSION

Date: August 30, 2004
Signature

Signature

Janet I. Cord

(type or print name of person certifying)

• Only the date of filing (§ 1.6) will be the date used in a patent term adjustment calculation, although the date on any certificate of mailing or transmission under § 1.8 continues to be taken into account in determining timeliness. See § 1.703(f). Consider "Express Mail Post Office to Addressee" (§ 1.10) or facsimile transmission (§ 1.6(d)) for the reply to be accorded the earliest possible filing date for patent term adjustment calculations.

90RM PTO 1449

U. S DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.	SERIAL NO.					
U 014698-7	10/613,414					
APPLICANT						
Selvakumar NATESAN ET AL.						
FILING DATE	GROUP					
07/03/2003	1614					

				0	7/03/2003	1614		
RE	FEREN	ICE DESIGNATION	U	S. PATENT DOCUM	MENTS	,		
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME		FILING DATE IF		
	АА	6,124,334	09/2000	Hutchinson				
	АВ	4,174,958	11/1979	Pilgram				
•	AC	3,651,079	03/1972	Skorez et al.				
	AD	4,910,341	03/1990	Lang				
			FOREIGN PATEN	NT DOCUMENTS				
		DOCUMENT			TRA	NSLATION		
		NUMBER	DATE	COUNTRY	YES	NO		
	AE	11-322729	11/1999	JP		×		
	AF	3536066	04/1986	DE		×		
	AG	2357591	05/1974	DE		×		
	АН	95/07271	03/1995	wo				
	ΑI	01/09107	02/2001	wo				
	AK	96/13502	05/1996	wo				
		OTHER ART	(Including Autho	r, Title, Date, Pertin	ent Dates, Etc.)			
	AL	Patent Abstracts of J	apan English languag	e abstract of JP 11-	322729, dated No	vember 24, 1999		
	АМ	U.S. Patent 4,910,341 corresponding to German Publication DE 3536066, dated April 17, 1986						
	AN	U.S. Patent 3,963,70	6 corresponding to G	erman Publication D	DE 2357591, dated	May 22, 1974		
	AO	Melissaris, A. P. and J. A. Mikroyannidis. "Thermally Stable Polymers Based on Bismaleimides Containing Amide, Imide and Ester Linkages", <i>J. Polymer Science: Polymer Chemistry Part A</i> (1989), 27: 245-262						
	АР	Artico, M. et al. "Research on Compounds with Antiblastic Activity", // Farmaco - Ed. Sci., (1969), 24(2): 179-190						
	AQ	Ueda, Minoru et al. "Syntheses and Novel Bioactivities of Artificial Leaf-Opening Substances of Lespedeza Cuneata G. Don, Designed for the Bioorganic Studies of Nyctinasty", Tetrahedron (1999), 55: 10925-10936						
		Ricca, Jean-Marc and David H.G. Crout. "Selectivity and Specificity in Substrate Binding to Proteases: Novel Hydrolytic Reactions Catalysed by α-Chymotrypsin" J. Chem. Soc. Perkin Trans. I (1993), 1225-1233						
	AR	Novel Hydrolytic Read 1225-1233	ctions Catalysed by α	-Chymotrypsin"。	J. Chem. Soc. Perk	in Trans. / (1993),		

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to

applicant.

FORM PTO-1449 U. S DEPARTMENT OF COMMERCE			ATTY. DOCKET NO.		SERIAL NO.			
PATENT AND TRADEMARK OFFICE			U 014698-7		10/613,414			
INFORMATION DISCLOSURE				APPLICANT				
STATEMENT BY APPLICANT				Selvakumar NATESAN ET AL.				
	(Use several sheets if	f necessary)		FIL	ING DATE	GROUP	
					07	7/03/2003	1614	
REI	FEREN	CE DESIGNATION	U	S. PATEN	T DOCUM	1ENTS		
EXAMINER INITIAL		DOCUMENT NUMBER	DATE		NAME firrmann		FILING DATE IF APPROPRIATE	
	AA	3,963,706	06/1976	Pfirrman				
-	AB		-					
	ÄC							
	AD							
			FOREIGN PATEN	IT DOCUM	//ENTS			
DOCUMENT						TRAI	RANSLATION	
		NUMBER	DATE	cour	NTRY	YES	NO	
	AE	97/27188	07/1997	w	'O			
	AF	03/011859	02/2003	W	'O			
	AG							
	АН							
	ΑI							
	AK							
		OTHER ART	(Including Autho	r, Title, Da	ite, Pertino	ent Dates, Etc.)		
								
	AL							
-				*		· · · · · · · · · · · · · · · · · · ·		
	AM							
	0.01							
	AN		- <u></u>					
	AO			•				
<u>-</u>								
	АР							
	AQ				_			
	AR							
EXAMINER DATE CONSIDERED								
EXAMINER:		nitial if citation conside	red whether or not o	itation is i	n conform	ance with MPEP 60	09: Draw line through	

citation if not in conformance and not considered. Include copy of this form with next communication to

applicant.